People above 65 years of age would amount to 10.7% of total population of India by 2021. India has acquired the label of ‘an ageing nation’ with 7.7% of its population being more than 60 years old. Geriatric patients are exposed to potentially inappropriate medications (PIMs) thus strategies to improve quality of life and safety of prescribing is needed. One such explicit criteria tool is ‘Screening Tool of Older person’s Potentially inappropriate Prescriptions’ (STOPP) criteria. For older individuals, frailty plays a decisive role. Frailty assessment is useful for identification of risk stratifications to assist in clinical decision makings. Hence, this study is aimed to assess the percentage of PIM using STOPP criteria and correlation between PIMS and Frailty Index (FI) in elderly patients in our setting. An observational study was done in 60 patients in department of medicine at tertiary care teaching hospital. Demographic details, diagnosis and current medications were recorded in Microsoft excel 2016. PIMs based on STOPP criteria version 2 and FI suggested by Searle et al. was calculated and analyzed. Spearman rank correlation test was used to check the correlation between FI and PIM. Out of 60 prescriptions, 21 prescriptions with PIM were found. Most common drugs prescribed as PIM were Aspirin, calcium, ceftriaxone, multivitamin B complex and furosemide. FI was analyzed by using 34 variables. Value of FI was between 0.03 to 0.17. Spearman Rank correlation test showed direct low degree of significant correlation between FI and PIM with correlation (r) value of 0.1602 (P value=0.02). 35% of prescriptions were having at least one PIM in our study and we found that there was direct association between FI and PIM which will help us to reduce potential medication errors, drug interactions and adverse reactions.
Purpose/aim: To assess the current prescription pattern, efficacy, tolerability and impact on Quality of life(QoL) in psoriasis patients. Material: An observational, prospective study of 18 months was carried out in a tertiary care teaching hospital. Newly diagnosed patients of psoriasis, aged ≥ 18 years were included in the study. The demographic, clinical profile, psoriasis area severity index (PASI) and drug utilization were recorded. Follow up was done at 15 days interval for two and a half months. Patient’s QoL was assessed using Psoriasis Disability Index (PDI). Results: A total 100 patients were enrolled in the study. At the time of diagnosis, 43 patients had PASI score ≤10 and 57 had > 10. At the last follow up 96 patients had PASI sore ≤ 10 and 4 had > 10. Mean of QoL at the time of diagnosis was 10.43 and at the last follow up 6.1. Pre and post-treatment PASI score showed direct intermediate significant correlation with pre and post-treatment QoL score. Most frequently fixed drug combination(FDC)of steroid and keratolytic agent were prescribed followed by anti-histaminics, steroids, minerals, anti-microbial agents, emollients, vitamins, H2-blockers, immunosuppressants, and NSAIDS.WHO core indicators were used to analyse drugs prescribed. Conclusions: In this study, the treatment of psoriasis is according to the “NICE” guideline. Patient’s treatment adherence increased because of the QoL improvement. Thus, the QoL tools are important measure of patient satisfaction and treatment monitoring. Keywords: Psoriasis area severity index, Psoriasis Disability Index, Quality of life, Drug Utilization in Psoriasis
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.